NCIt definition : A humanized monoclonal antibody directed against the immunosuppressive ligand programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential
immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1
monoclonal antibody LP002 specifically targets and binds to PD-L1, blocking its binding
to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation
279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and
enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against
PD-L1-expressing tumor cells. In addition, by binding to PD-L1, LP002 also prevents
binding of this ligand to B7.1 expressed on activated T cells, which further enhances
the T-cell-mediated immune response. PD-L1 is overexpressed by many human cancer cell
types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in
immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily
(IgSF) expressed on activated T-cells, is a negative regulator of the immune system
that limits the expansion and survival of CD8-positive T-cells.;